¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Bloodborne Path Per Pro Ref Misc"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lateral condyle path
    ¿ÜÃø°ú·Î.
  • lateral incisal path
    Ãø¹æÀýÄ¡·Î(ö°Û°ôîöÍÖØ).
  • optical path
    ±¤·Î(ÎÃÖØ).
  • particle path
    ÀÔÀÚÅë·Î(í£í­÷×ÖØ).
  • path
    °æ·Î, Åë·Î, ÆÐ½º
  • pupillary reflex path
    µ¿°ø¹Ý»ç°æ·Î(¡­ÌèÖØ).
  • reflex path =r. pathway, r. tract
    ¹Ý»ç°æ·Î(ÚãÞÒÌèÖØ).
  • strionigral path
    ¼±»óÃ¼ÈæÁú·Î(àÊß¾ô÷ýÙòõÖØ).
  • cardiac minute output =c. m. volume, c. output per minute
    ¸ÅºÐ(½É)¹ÚÃâ·®(ØßÝÂãýÚÑõóåÖ).
  • contagio per contactum<³ª>
    Á¢ÃËÀü¿°(ÊÙËøËç).
  • contagio per contactum<³ª>
    Á¢ÃËÀü¿°(¡­îîæø).
  • contagio per formitem<³ª>
    ¸Å°³¹°Àü¿°(ËÎ˧ËÑËøËç).
  • contagio per formitem<³ª>
    ¸Å°³¹°Àü¿°(ØÚ˿ڪîîæø).
  • cycle per second
    Ãʰ£Áøµ¿¼ö.
  • cycle per second(=cps, Hz)
    Ãʰ£(ôøÊÊ)Áøµ¿¼ö(òÉÔÑâ¦).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
Ref Doc referring doctor
ref ind refractive index
Ref Phys referring physician
ARP absolute refractory period; American Registry of Pathologists; anticipated recovery path; apolipopro...
CPM central pontine myelinosis; chlorpheniramine maleate; continuous passive motion; critical path metho...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
pro-enk A pro-enkephalin A
PM/PM per member per month
MPP Medial perforant path
PP Perforant Path
LPP lateral perforant path
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • functionally generated path
    ±â´É ¿îµ¿·Î
  • incisor path recording apparatus
    Àý´Ü·Î ¹¦»ç±â
    Gysi´Â ÇÏ¾Ç ¿îµ¿À» ±âÇÏÇÐÀûÀ¸·Î ¿¬±¸Çϱâ À§ÇÏ¿© ÇÏ¾Ç ÀüÄ¡ºÎÀÇ ¿îµ¿ ±ËÀûÀ» ±³ÇÕÆò¸é ¹× Á¤Á߸鿡 À־ ±â·ÏÇÏ´Â ÀåÄ¡¸¦ °í¾ÈÇß´Ù. ¹¦»ç±â´Â ÇÏ¾Ç ±³ÇÕÁ¦ Àü¸é¿¡ ÀåÄ¡µÈ´Ù. ¹¦±âħÀÇ Çϳª´Â ±³ÇÕ Æò¸é¿¡ À־ÀÇ ÀüÄ¡ºÎ Ãø¹æ ¿îµ¿ÀÇ ±ËÀûÀ» ±â·ÏÇϱâ À§ÇÏ¿© »ó¹æ ±³ÇÕÁ¦¿¡ ÇÏÇâÀ¸·Î, ´Ù¸¥ Çϳª´Â Á¤Áß¸é »óÀÇ °³Æó ¿îµ¿ ±ËÀûÀÌ ±â·ÏµÇ°Ô²û ¿·À¸·Î ÇâÇÏ¿© ÀåÄ¡µÇ¾î ÀÖ´Ù.
  • inclination of sagittal incisal path
    ½Ã»ó ÀýÄ¡·Î °¢
    1. ÇϾÇÀÇ ÀüÁø ¿îµ¿¿¡ À־, ÇÏ¾Ç ÀüÄ¡Á¡Àº ÀüÇϹæÀ¸·Î À̵¿Çؼ­ ½Ã»ó ÀüÄ¡·Î °¢À» ±×¸®´Âµ¥ ±× Á¦ 1»óÀÌ ±³ÇÕ Æò¸é°ú ÀÌ·ç´Â °¢À» ½Ã»ó ÀüÄ¡·Î °¢À̶ó°í ÇÑ´Ù. Gysi¿¡ ÀÇÇϸé 40?~80?, Nakasawa¿¡ ÀÇÇϸé 0?~62?, Æò±Õ 34?ÀÌ´Ù. ¹«Ä¡¾Ç¿¡¼­´Â °íÀ¯ÀÇ ¼öÄ¡°¡ ¾øÀ¸³ª, ±¸Ä¡ºÎ ±³µÎ°æ»ç¿Í Á¤ºñ·ÊÀûÀ¸·Î °ü°èµÇ¾î, ÀÇÄ¡ÀÇ ±â´É°ú °ü°è°¡ ±íÀ¸¹Ç·Î µµÄ¡ ¹è¿­ ½Ã¿¡ Àû´çÈ÷ Á¶Àý, ¼³Á¤ÇÑ´Ù. Æò±Õ½Ä±³±³±â¿¡¼­´Â 10?ÀÇ °ÍÀÌ ¸¹´Ù. 2. ÇϾÇÀÇ Ãø¹æ ¿îµ¿ ½Ã¿¡ ÀüÄ¡Á¡Àº Á¿ìÃøÀÇ Àü¿ÜÇϹæÀ¸·Î À̵¿ÇÏ¿© ¼ÒÀ§ °íµñ¾ÆÄ¡¸¦ ±×¸°´Ù. ÀÌ¿¡ ÀÇÇÏ¿© ¾ò¾îÁø °¢ÀÇ ±³ÇÕ Æò¸é¿¡ Åõ¿µÇÑ °¢À» Ãø¹æ ÀýÄ¡·Î °æ»çµµ¶ó°í Çϸç, Gysi¿¡ ÀÇÇÏ¿© Æò±Õ 120?¶ó°í ÇÑ´Ù. ±¸Ä¡ºÎÀÇ ±³µÎ °æ»ç¿Í ¿ªºñ·ÊÀûÀÎ °ü°è¸¦ ³ªÅ¸³½´Ù.
  • milled-in path
    ±â·Ï·Î, ¸¶¸ð ±³ÇÕ·Î, ÀÚµ¿ ¸¶¸ð ±³ÇÕ ¸¸°î
    ÇϾǰñÀÌ ¿îµ¿À» ÇÒ ¶§, »ó´ëµÇ´Â ±³ÇÕ ¸é¿¡´Â Ä¡¾Æ³ª ¾î¶² ÀåÄ¡°¡ µÇ¾î ÀÖ¾î À̰ÍÀÌ ±³ÇÕÁ¦ÀÇ ±³ÇÕ ¸é¿¡ ÀÚµ¿ÀûÀ¸·Î Á¶°¢µÇ¾î ³ªÅ¸³­ »óÅÂ.
  • occlusal path registration
    ±³ÇÕ·Î ±â·Ï
    ȯÀÚ ±¸°­ ³»¿¡¼­ ´ëÇÕÄ¡¿¡ ÀÇÇÏ¿© wax¿¡ ÀαâµÇ°Å³ª ±â·ÏµÈ ±³ÇÕ·ÎÀÇ ±â·Ï.
  • path
    °æ·Î, Åë·Î, ÆÐ½º
    Áö³ª°¡´Â ¶Ç´Â Ⱦ´ÜÇϴ Ư¼öÇÑ Åë·Î. ½Å°æÇп¡¼­´Â ±¸½É¼º, ¶Ç´Â ¿ø½É¼ºÀ¸·Î ½Å°æ Ãæµ¿À» Àü´ÞÇÏ´Â ½Å°æ ¼¶À¯ÀÇ ÇÑ °æ·Î·Î¼­, ƯÈ÷ ±× °æ·ÎÀÇ µÎ°³³» ¹× ô¼ö³» ºÎºÐÀ» ¸»ÇÑ´Ù.
  • path of insertion
    »ðÀÔ·Î
    º¸Ã¶¹°ÀÌ Áö´ëÄ¡ÀÇ Ã³À½ Á¢ÃËÁ¡À¸·ÎºÎÅÍ ±¹¼Ò ÀÇÄ¡ÀÇ ·¹½ºÆ®¿Í ÀÇÄ¡»óÀÌ Á¦ À§Ä¡¿¡ µé¾î°¡´Â ÃÖÁ¾ ¾ÈÁ¤ À§Ä¡±îÁö º¸Ã¶¹°ÀÌ ¿òÁ÷ÀÌ´Â ¹æÇâ.
  • path of placement
    »ðÀÔ·Î
  • ray path
    ±¤¼±·Î
  • rotating path
    ȸÀü °æ·Î
  • rotational path removable partial denture
    ȸÀü °æ·Î·Î ÀåÂøÇÏ´Â °¡Ã¶¼º ºÎºÐ»ó ÀÇÄ¡
  • sagittal path of condyle
    °úµÎÀÇ ½Ã»ó·Î
    ÀúÀÛ ½Ã ÇϾǰñÀÇ °üÀý µ¹±âÀÇ ¿îµ¿ °æ·Î¸¦ ½Ã»ó¸é¿¡ Åõ¿µ½ÃŲ °Í. ¿Õ·Î¿Í º¹·Î¿Í´Â ´ë°³ÀÇ °æ¿ì ÀÏÄ¡ÇÏÁö ¾Ê°í, ¶Ç ¹Ýº¹ ÀúÀÛÇÒ ¶§ ¸ÅÀÏ µ¿ÀÏ °æ·Î¸¦ ÃëÇÑ´Ù°í´Â Á¤ÇØÁ® ÀÖÁö ¾Ê´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
pro- <prefix> Prefix (from both Greek and Latin) with many meanings including before, in front of, preceding, on behalf of, in place of, and the same as. Used as a word, pro of course means professional and, in medicine, it is short for prothrombin.
(12 Dec 1998)
pro-lactase-phlorizin hydrolase <chemical>
Synonym: pro-lph
(26 Jun 1999)
pro-ocytocin-neurophysin convertase <enzyme> Cleaves pro-ocytocin-neurophysin at the cooh-terminal side of arg 12 to release the bioactive peptide
Registry number: EC 3.4.99.-
Synonym: pro-ot-np convertase, pro-oxytocin-neurophysin convertase
(26 Jun 1999)
pro opimelanocortin <protein> Polyprotein produced by the anterior pituitary that is cleaved to yield adrenocorticotrophin, _, _ and _ melanocyte stimulating hormones, lipotropic hormones, _ endorphin and other fragments.
(18 Nov 1997)
pro-opiomelanocortin <chemical> A precursor protein, mw 30,000, synthesised mainly in the anterior pituitary gland but also found in the hypothalamus, brain, and several peripheral tissues. It incorporates the amino acid sequences of acth and beta-lipotropin. These two hormones, in turn, contain the biologically active peptides msh, corticotropin-like intermediate lobe peptide, alpha-lipotropin, endorphins, and methionine enkephalin.
Chemical name: Opiomelanocortin, pro-
(12 Dec 1998)
pro-oxidants Compounds or agents capable of generating toxic oxygen species.
Compare: antioxidant.
(05 Mar 2000)
pro re nata As the occasion arises; as necessary.
Acronym: prn
Origin: L.
(05 Mar 2000)
pro-transforming growth factor-alpha processing protease <enzyme> Converts membrane-bound protgf-alpha to soluble tgf-alpha; mw 84 kD
Registry number: EC 3.4.21.-
Synonym: protgf-alpha converting enzyme, protgfalpha processing protease
(26 Jun 1999)
X-Pro aminopeptidase <enzyme> Proline specific exopeptidase
Registry number: EC 3.4.11.9
Synonym: x-prolyl aminopeptidase, proline-specific exopeptidase, aminopeptidase p
(26 Jun 1999)
per- 1. <prefix> A prefix used to signify through, throughout, by, for, or as an intensive as perhaps, by hap or chance; perennial, that lasts throughout the year; perforce, through or by force; perfoliate, perforate; perspicuous, evident throughout or very evident; perplex, literally, to entangle very much.
2. <chemistry> Originally, denoting that the element to the name of which it is prefixed in the respective compounds exercised its highest valence; now, only that the element has a higher valence than in other similar compounds; thus, barium peroxide is the highest oxide of barium; while nitrogen and manganese peroxides, so-called, are not the highest oxides of those elements.
(29 Oct 1998)
per anum By or through the anus.
Origin: L.
(05 Mar 2000)
per capita rate <epidemiology> A rate which is proportional to the number of individuals in a population.
(05 Dec 1998)
per contiguum In contiguity; denoting the mode by which an inflammation or other morbid process spreads into an adjacent contiguous structure.
Origin: per-+ L. Contiguus, touching, fr. Tango, to touch
(05 Mar 2000)
per continuum In continuity; continuous; denoting the mode by which an inflammation or other morbid process spreads from one part to another through continuous tissue.
Origin: per-+ L. Continuus, holding together, continuous, fr. Teneo, to hold
(05 Mar 2000)
per orally To take a medication by mouth.
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • pro
    ÇÁ·Î
  • pro-
    ´ë½Å
  • Pro. Station
    ¼ºº´ ¿¹¹æ½Ã¼³
  • pro
    ÇÁ·Î;Àü¹®°¡;Á÷¾÷¼±¼ö;Á÷¾÷ÀûÀÎ;Á÷¾÷¼±¼öÀÇ;ÇÁ·ÎÀÇ
  • pro
    Âù¼ºÇÏ¿©(pro and con ÂùºÎ µÎ °¥·¡·Î);ÂùºÎ¾ç·Ð(pros and cons ÂùºÎ¾çÆù,ÂùºÎÀÇ ÀÌÀ¯)
  • pro
    ¸ÅÃáºÎ
  • pro number
    (¹ß¼ÛÀÇ) ´©Áø ¹øÈ£
  • pro patria
    Á¶±¹À» À§ÇÏ¿©
  • pro tanto
    ±× Á¤µµ±îÁö
  • pro tempore
    Àӽ÷Î;´çºÐ°£;ÀϽÃÀûÀ¸·Î
  • pro tempore
    ÀϽÃÀûÀ¸·Î;Àá½ÃÀûÀ¸·Î;Àӽ÷Î
  • pro-
    ...À» À§ÇÏ¿©
  • quid pro quo
    ´ë»ó¹°
  • per
    -¿¡ ´ëÇØ,-¸¶´Ù
  • per cent
    ÆÛ¼¾Æ®
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á